Display options
Cite
Sadr-Azodi O, Konings P, Brusselaers N. Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study. United European Gastroenterol J. 2017;5(8):1123-1128doi: 10.1177/2050640617702060.
Sadr-Azodi, O., Konings, P., & Brusselaers, N. (2017). Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study. United European gastroenterology journal, 5(8), 1123-1128. https://doi.org/10.1177/2050640617702060
Sadr-Azodi, Omid, et al. "Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study." United European gastroenterology journal vol. 5,8 (2017): 1123-1128. doi: https://doi.org/10.1177/2050640617702060
Sadr-Azodi O, Konings P, Brusselaers N. Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study. United European Gastroenterol J. 2017 Dec;5(8):1123-1128. doi: 10.1177/2050640617702060. Epub 2017 Apr 09. PMID: 29238591; PMCID: PMC5721980.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2017 Dec;5(8):1123-1128. doi: 10.1177/2050640617702060. Epub 2017 Apr 09.

Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study.

United European gastroenterology journal

Omid Sadr-Azodi, Peter Konings, Nele Brusselaers

Affiliations

  1. Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  2. Department of Surgery, Eskilstuna County Hospital, Eskilstuna, Sweden.
  3. Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden.
  4. Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

PMID: 29238591 PMCID: PMC5721980 DOI: 10.1177/2050640617702060

Abstract

BACKGROUND: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design.

METHODS: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression.

RESULTS: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23% reduced risk (OR 0.77; 95% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR) 0.65; 95% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60% (IRR 0.40; 95% CI: 0.18-0.88) in women who used MHT ≥ 3 years compared to women with <1 year of MHT use. The type of MHT did not change the results.

CONCLUSION: Systemic MHT use might reduce the risk of pancreatic cancer.

Keywords: Menopausal hormone therapy; epidemiology; etiology; pancreatic cancer; population-based study

References

  1. Int J Cancer. 2010 May 15;126(10):2394-403 - PubMed
  2. Cancer Epidemiol. 2010 Dec;34(6):696-701 - PubMed
  3. Int J Pancreatol. 1990 Aug-Nov;7(1-3):159-65 - PubMed
  4. Am J Epidemiol. 2013 Nov 1;178(9):1403-13 - PubMed
  5. Ann Surg Oncol. 2007 Apr;14(4):1320-6 - PubMed
  6. Ann Oncol. 2008 Jan;19(1):150-5 - PubMed
  7. Anticancer Res. 2010 Nov;30(11):4619-24 - PubMed
  8. Pancreas. 2007 Aug;35(2):120-9 - PubMed
  9. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):433-8 - PubMed
  10. Pancreas. 2011 Apr;40(3):460-3 - PubMed
  11. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35 - PubMed
  12. Pancreas. 2005 May;30(4):369-74 - PubMed
  13. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  14. J Gastroenterol Hepatol. 2007 Sep;22(9):1469-73 - PubMed
  15. JAMA. 2001 Aug 22-29;286(8):921-9 - PubMed
  16. Am J Epidemiol. 2005 Apr 15;161(8):741-7 - PubMed
  17. JAMA. 2009 Jun 24;301(24):2553-62 - PubMed
  18. Cancer Causes Control. 2005 Nov;16(9):1035-40 - PubMed
  19. JOP. 2007 Jan 09;8(1):16-27 - PubMed
  20. Cancer Res. 1986 May;46(5):2276-81 - PubMed
  21. Br J Cancer. 2013 Nov 26;109(11):2924-32 - PubMed
  22. Int J Cancer. 1995 Jul 4;62(1):11-4 - PubMed
  23. Br J Surg. 1997 Aug;84(8):1085-9 - PubMed
  24. Ann Surg. 2011 Aug;254(2):311-9 - PubMed
  25. Cancer Causes Control. 2010 Mar;21(3):473-8 - PubMed
  26. J Surg Res. 2007 Jun 1;140(1):55-66 - PubMed
  27. Eur J Epidemiol. 2009;24(11):659-67 - PubMed

Publication Types